PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION

The aim – assess the clinical advantages and economic burden of various treatment strategies in patients with hemophilia A in the Russian Federation and propose the ways of optimizing this area of medical care.Materials and methods. A mathematical model describing the current (2017) approach to ther...

Full description

Bibliographic Details
Main Authors:	M. Yu. Frolov, V. A. Rogov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2018-02-01
Series:	Фармакоэкономика
Subjects:	hemophilia a prophylaxis personalized prophylaxis cost-effectiveness analysis pharmacoeconomics
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/212

Similar Items

Clinical practice of personalized prophylaxis in hemophilia: Illustrations of experiences and benefits from two continents
by: Shannon Jackson, et al.
Published: (2019-04-01)

PHARMACOECONOMIC ANALYSIS OF EFFICACY OF DIFFERENT MODES OF ANTIBIOTIC PROPHYLAXIS IN CHOLECYSTECTOMY
by: A. N. Poborskiy, et al.
Published: (2016-10-01)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
by: Byung Suk Moon, et al.
Published: (2013-07-01)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
by: Djambas Khayat C
Published: (2016-11-01)

Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
by: Jing Sun, et al.
Published: (2021-06-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
by: Midori Shima
Published: (2020-05-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

FREQUENCY AND DEGREE OF CHRONIC ARTHROPATHY IN HEMOPHILIA A PATIENTS ON PROPHYLACTIC AND ON-DEMAND TREATMENT
by: Miodrag Vučić, et al.
Published: (2016-03-01)

Platelet function and microvesicle generation in patients with hemophilia A
by: Antonia Melero‐Amor, et al.
Published: (2021-03-01)

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
by: Le Quellec S
Published: (2020-02-01)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
by: Saunya Dover, et al.
Published: (2020-02-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement
by: Gue D, et al.
Published: (2015-12-01)

Hemophilia Care in the Pediatric Age
by: Marta Bertamino, et al.
Published: (2017-05-01)

Aggressive Neuroblastoma in a Pediatric Patient with Severe Hemophilia A
by: Lidia Costa, et al.
Published: (2021-03-01)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
by: Runhui Wu, et al.
Published: (2021-08-01)

Evaluation of efficacy of twice-weekly prophylactic treatment with BeneFIX® (recombinant factor IX) followed by once weekly in children with severe hemophilia B: Six-year data from a local registry
by: Rafal Raad Al-Janabi, et al.
Published: (2021-01-01)

Appropriateness and pharmacoeconomics of surgical antimicrobial prophylaxis in open reduction internal fixation surgery practiced in a tertiary hospital compared to recommendations in the national center for disease control guidelines
by: Priyanka Kumari, et al.
Published: (2019-01-01)

Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
by: Benson G, et al.
Published: (2021-01-01)

Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly
by: Dorina Cultrera, et al.
Published: (2020-01-01)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
by: Wu R, et al.
Published: (2020-06-01)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
by: Jerome Teitel, et al.
Published: (2021-02-01)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
by: Johnny Mahlangu, et al.
Published: (2021-08-01)

Pharmacoeconomic particulars of ovaries cancer’s treatment
by: V N Zhurman, et al.
Published: (2015-06-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

Pharmacoeconomic Analysis of Hemophilia Care in Romania
by: Petre Serban, et al.
Published: (2020-12-01)

Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia A
by: Prakas Kumar Mandal, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Pharmacoeconomic aspects of schizophrenia
by: Dutina Aleksandra, et al.
Published: (2018-01-01)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
by: Pocoski J, et al.
Published: (2016-07-01)

Developing an economic case of clinical pharmacists' interventions on venous thromboembolism prophylaxis through service evaluation
by: Eun Hee Lee, et al.
Published: (2017-01-01)

Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2020-07-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

PHARMACOECONOMICS OF APPLICATION OF HEPATOPROTECTORS IN THERAPY OF DRUG-INDUCED LIVER INJURY AFTER CHEMOTHERAPY
by: D. D. Morikov, et al.
Published: (2017-04-01)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
by: Anthony K. Chan, et al.
Published: (2020-10-01)

PHARMACOECONOMIC EVALUATION OF ANTI-PNEUMOCOCCAL VACCINATION IN RISK GROUPS FOR THE PREVENTION OF COMMUNITY-ACQUIRED PNEUMONIA AMONG ADULTS IN THE ASTRAKHAN REGION
by: E. A. Orlova, et al.
Published: (2021-05-01)

SOCIAL PREVENTION OF TUBERCULOSIS IN THE ARMED FORCES OF THE RUSSIAN FEDERATION
by: R. D. Muchaidze, et al.
Published: (2015-03-01)

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION
by: S. G. Gorokhova, et al.
Published: (2012-08-01)

Cannot write session to /tmp/vufind_sessions/sess_cvvonlusihjocjaah8uarb0435